Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders
2024

Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders

Sample size: 632 publication Evidence: moderate

Author Information

Author(s): Bárbara Fernandes Gomes, Atul Kumar, Ashton Nicholas J, Sara Hall, Erik Stomrud, Ruben Smith, Henrik Zetterberg, Kaj Blennow, Niklas Mattsson-Carlgren, Oskar Hansson

Primary Institution: The Sahlgrenska Academy at the University of Gothenburg

Hypothesis

Is corticotropin-releasing hormone (CRH) a potential biomarker for parkinsonian syndromes?

Conclusion

CRH is a promising biomarker for Lewy body disease and atypical parkinsonian syndromes, showing associations with cognitive impairment and inflammation.

Supporting Evidence

  • CRH was downregulated in αSyn positive Lewy body disease and atypical PS compared to controls.
  • CRH levels correlated with cognitive impairment in Lewy body disease patients.
  • CRH was decreased in de novo Lewy body disease patients not on dopaminergic medication.

Takeaway

This study found that a hormone called CRH is lower in people with certain brain diseases, which might help doctors tell these diseases apart.

Methodology

The study analyzed CSF CRH levels in two independent cohorts using proximity extension assays and compared them across different groups.

Limitations

The study lacked longitudinal clinical data and some subgroup analyses had low sample sizes.

Participant Demographics

Participants included individuals with Lewy body disease, atypical parkinsonian syndromes, non-parkinsonian neurodegenerative diseases, and cognitively unimpaired controls.

Statistical Information

P-Value

3.3e−05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1093/braincomms/fcae414

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication